Previous close | 144.60 |
Open | 144.60 |
Bid | 123.00 |
Ask | 131.00 |
Strike | 310.00 |
Expiry date | 2025-01-17 |
Day's range | 144.60 - 144.60 |
Contract range | N/A |
Volume | |
Open interest | 717 |
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.